We developed a fully immunocompetent, genetically engineered mouse model (GEMM) for pDMG and pHGG that incorporates the glioma-associated antigen, IL13RA2 and demonstrated the suitability of the model for evaluation of targeted therapy such as CAR T cells. The gene discussed is IL13RA2; the disease is central nervous system cancer.